Allarity Therapeutics, Inc.
stenoparib
advanced ovarian cancer
Date
TBD
FDA decision · Date TBD estimated
What's at stake
An FDA complete response letter on stenoparib for advanced ovarian cancer is in focus around Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“the FDA’s Fast Track designation for stenoparib underscores both the encouraging clinical benefit we have observed to date and the significant unmet medical need in this patient population.”